Wyniki wyszukiwania

1

The current view on biological potency of cationically modified chitosan

100%

Stefan J., Lorkowska-Zawicka B., Kaminski K., Szczubialka K., Nowakowska M., Korbut R.

Journal of Physiology and Pharmacology

|

2014

|

tom 65

|

nr 3

2

The antiatherogenic effect of new biocompatible cationically modified polysaccharides: chitosan and pullulan - the comparison study

100%

Stefan J., Kus K., Wisniewska A., Lorkowska-Zawicka B., Kaminski K., Szczubialka K., Nowakowska M., Korbut R.

Journal of Physiology and Pharmacology

|

2018

|

tom 69

|

nr 6

3

Heart rate reduction with ivabradine in the early phase of atherosclerosis is protective in the endothelium of ApoE-deficient mice

100%

Aquila G., Morelli M. B., Vieceli Dalla Sega F., Fortini F., Nigro P., Caliceti C., Ferracin M., Negrini M., Pannuti A., Bonara M., Pinton P., Ferrari R., Rizzo P.

Journal of Physiology and Pharmacology

|

2018

|

tom 69

|

nr 1

4

New cationically modified pullulan attenuates atherogenesis and influences lipid metabolism in apoE-knockout mice

100%

Stefan J., Kus K., Wisniewska A., Kaminski K., Szczubialka K., Jawien J., Nowakowska M., Korbut R.

Journal of Physiology and Pharmacology

|

2016

|

tom 67

|

nr 5

5

Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice

80%

Jawien J., Toton-Zuranska J., Gajda M., Niepsuj A., Gebska A., Kus K., Suski M., Pyka-Fosciak G., Nowak B., Guzik T. J., Marcinkiewicz J., Olszanecki R., Korbut R.

Journal of Physiology and Pharmacology

|

2012

|

tom 63

|

nr 1

6

Mouse models of experimental atherosclerosis

80%

Jawien J., Nastalek P., Korbut R.

Journal of Physiology and Pharmacology

|

2004

|

tom 55

|

nr 3

Since 1992 the mouse has become an excellent model for experimental atherosclerosis research. Until 1992, the diet - induced atherosclerosis mouse model has been used effectively, but the lesions tended to be small and were limited to early fatty-streak stage. This model was also criticized because of the toxicity and inflammatory responses due to the diet. In 1992 the first line of gene targeted animal models, namely apolipoprotein E - knockout mice was developed. Of the genetically engineered models, the apoE - deficient model is the only one that develops extensive atherosclerotic lesions on a chow diet. It is also the model in which the lesions have been characterized most thoroughly. The lesions develop into fibrous plaques; however, there is no evidence that plaque rupture occurs in this model. The LDL receptor - deficient model has elevated LDL levels, but no lesions, or only very small lesions, form on the chow diet, however, robust lesions do form on the western-type diet. The creation of apoE - knockout mice has changed the face of atherosclerosis research.

Ograniczanie wyników

The current view on biological potency of cationically modified chitosan

The antiatherogenic effect of new biocompatible cationically modified polysaccharides: chitosan and pullulan - the comparison study

Heart rate reduction with ivabradine in the early phase of atherosclerosis is protective in the endothelium of ApoE-deficient mice

New cationically modified pullulan attenuates atherogenesis and influences lipid metabolism in apoE-knockout mice

Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice

Mouse models of experimental atherosclerosis